MedTrace Logo

The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43

NCT02457104 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-02-18

No results posted yet for this study

Summary

The investigators long-term goal is to understand how PPIs influence energy balance in both obese and normal-weight individuals. The overall goal of this study is to determine whether PPI use causes detrimental changes in the composition and functional properties of the gut microbiome, and whether any such effects are mediated by altered responses of human fatty acid receptors (e.g., GPR41/43).

Conditions

  • Gastroesophageal Reflux Disease
  • Obesity

Interventions

PROCEDURE

Colonoscopy

Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.

BEHAVIORAL

Weight and diet questionnaire

Brief questionnaire outlining weight history, type and dose of PPI, and diet.

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Jennifer Czwornog, MD · University of Colorado, Denver

Eligibility

Min Age
40 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2021-10-31
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02457104 on ClinicalTrials.gov